Sökning: onr:"swepub:oai:lup.lub.lu.se:d8184a98-8c7f-41d6-a80e-4a39b20d9587" >
Rivaroxaban versus ...
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
-
- Lassen, Michael R (författare)
- Nordsjællands Hospital
-
- Ageno, Walter (författare)
- University of Insubria
-
- Borris, Lars C (författare)
- Aarhus University Hospital
-
visa fler...
-
- Lieberman, Jay R (författare)
- University of Connecticut
-
- Rosencher, Nadia (författare)
- Cochin Hospital
-
- Bandel, Tiemo J (författare)
- Bayer Corporation, USA
-
- Misselwitz, Frank (författare)
- Bayer Corporation, USA
-
- Turpie, Alexander G G (författare)
- McMaster University
-
Levine, M (creator_code:cre_t)
-
- Flondell, M. (creator_code:cre_t)
- Lund University,Lunds universitet,Medicinska fakulteten,Faculty of Medicine
-
Wykman, A (creator_code:cre_t)
-
visa färre...
-
(creator_code:org_t)
-
- 2008
- 2008
- Engelska.
-
Ingår i: The New England journal of medicine. - 0028-4793. ; 358:26, s. 86-2776
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty.METHODS: In this randomized, double-blind trial, 2531 patients who were to undergo total knee arthroplasty received either oral rivaroxaban, 10 mg once daily, beginning 6 to 8 hours after surgery, or subcutaneous enoxaparin, 40 mg once daily, beginning 12 hours before surgery. The primary efficacy outcome was the composite of any deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause within 13 to 17 days after surgery. Secondary efficacy outcomes included major venous thromboembolism (i.e., proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death related to venous thromboembolism) and symptomatic venous thromboembolism. The primary safety outcome was major bleeding.RESULTS: The primary efficacy outcome occurred in 79 of 824 patients (9.6%) who received rivaroxaban and in 166 of 878 (18.9%) who received enoxaparin (absolute risk reduction, 9.2%; 95% confidence interval [CI], 5.9 to 12.4; P<0.001). Major venous thromboembolism occurred in 9 of 908 patients (1.0%) given rivaroxaban and 24 of 925 (2.6%) given enoxaparin (absolute risk reduction, 1.6%; 95% CI, 0.4 to 2.8; P=0.01). Symptomatic events occurred less frequently with rivaroxaban than with enoxaparin (P=0.005). Major bleeding occurred in 0.6% of patients in the rivaroxaban group and 0.5% of patients in the enoxaparin group. The incidence of drug-related adverse events, mainly gastrointestinal, was 12.0% in the rivaroxaban group and 13.0% in the enoxaparin group.CONCLUSIONS: Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total knee arthroplasty, with similar rates of bleeding. (ClinicalTrials.gov number, NCT00361894.)
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Nyckelord
- Adult
- Aged
- Aged, 80 and over
- Anticoagulants/adverse effects
- Arthroplasty, Replacement, Knee
- Double-Blind Method
- Enoxaparin/adverse effects
- Factor Xa Inhibitors
- Female
- Humans
- Male
- Middle Aged
- Morpholines/adverse effects
- Pulmonary Embolism/epidemiology
- Rivaroxaban
- Thiophenes/adverse effects
- Venous Thromboembolism/epidemiology
- Venous Thrombosis/epidemiology
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lassen, Michael ...
-
Ageno, Walter
-
Borris, Lars C
-
Lieberman, Jay R
-
Rosencher, Nadia
-
Bandel, Tiemo J
-
visa fler...
-
Misselwitz, Fran ...
-
Turpie, Alexande ...
-
Levine, M
-
Flondell, M.
-
Wykman, A
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kirurgi
- Artiklar i publikationen
-
The New England ...
- Av lärosätet
-
Lunds universitet